Clinical Study of Anlotinib in Maintenance Treatment of Advanced NSCLC
Status:
Unknown status
Trial end date:
2020-12-31
Target enrollment:
Participant gender:
Summary
Based on the need of clinical practice of maintenance therapy for advanced NSCLC and the
reliable data of third-line treatment for non-small cell lung cancer, the investigators
designed a clinical study of antinil hydrochloride versus pemetrexed in maintenance therapy
for advanced NSCLC to prospectively evaluate the efficacy of antinil hydrochloride in
maintenance therapy for advanced NSCLC. Value, to provide a scientific basis for prolonging
the survival time of patients with advanced NSCLC, improving the quality of life of patients
in the course of treatment, and optimizing treatment strategies to a greater extent.
Phase:
N/A
Details
Lead Sponsor:
The First Affiliated Hospital with Nanjing Medical University
Collaborators:
Huai'an First People's Hospital Jiangsu Taizhou People's Hospital The Affiliated Hospital of Xuzhou Medical University The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School Yancheng City NO.1 People's Hospital Zhongda Hospital